Loading cart...
Capecitabine 500 mg
Medically reviewed by Sanjay Gangani, B.Pharm, CMO & Pharmacist
| Active Ingredient | Capecitabine |
|---|---|
| Indication | Ovarian cancer, Head and neck cancer, Cervical cancer |
| Manufacturer | American Remedies Pvt. Ltd |
| Strength:- | 500mg |
| Packaging | 10 tablets in 1 strip |
Capecitabine 500 mg | ||||
|---|---|---|---|---|
| Pack Size | Price | Quantity | Add To Cart | |
| 100 Tablet/s | $70 | |||
| 200 Tablet/s | $130 | |||
| 300 Tablet/s | $185 | |||
What is Capecitabine 500 mg
Product identity
| Field | Detail |
| Generic name | Capecitabine |
| Strength covered here | 500 mg per tablet |
| Other strength | 150 mg |
| Dosage form | Film-coated tablet, oral |
| Appearance of 500 mg | Peach, oblong |
| Appearance of 150 mg | Light peach, oblong |
| Drug class | Oral fluoropyrimidine, antimetabolite |
| Converts to | Fluorouracil, also called 5-FU |
| Usual frequency | Twice daily, about 12 hours apart |
| Cycle | 14 days on, 7 days off, in 21-day cycles |
| Reference brand | Xeloda |
| Indian brand checked | Capnat 500 mg, Natco Pharma Ltd |
| Pack checked | Pack of 10 tablets |
| MRP of that pack | Rs. 1,687.50, with an old MRP of Rs. 1,800 |
| Prescription status | Prescription required |
| Storage | Below 30 degrees Celsius |
| Reference labels used | US FDA Xeloda, an Indian generic PI, EMA |
How it works (mechanism of action)
Dosage guide
Your oncologist sets your dose. These are the labelled regimens.
Approved regimens, all taken twice daily
| Setting | Dose twice daily | Schedule |
| Adjuvant colon, single agent | 1,250 mg/m2 | Days 1 to 14, 8 cycles |
| Adjuvant colon, with oxaliplatin | 1,000 mg/m2 | Days 1 to 14, 8 cycles |
| Rectal, with radiation | 825 mg/m2 | Perioperative |
| Rectal, without radiation | 1,250 mg/m2 | Perioperative |
| Metastatic colorectal, single agent | 1,250 mg/m2 | Days 1 to 14 |
| Metastatic colorectal, with oxaliplatin | 1,000 mg/m2 | Days 1 to 14 |
| Breast, single agent | 1,000 or 1,250 mg/m2 | Days 1 to 14 |
| Breast, with docetaxel | 1,000 or 1,250 mg/m2 | Days 1 to 14 |
How to take it
Precautions
Absolute contraindications
Conditions to disclose to your doctor
Food and drink precautions
Before-use safety checklist
Side effects
Rates differ by cancer and by whether other drugs are given.
Common side effects with reported rates
| Side effect | Reported rate | Severe grade 3 or 4 |
| Hand and foot reaction | 54% to 63% | 11% to 24% |
| Diarrhoea | 47% to 67% | 12% to 14% |
| Mouth soreness, stomatitis | Up to 67% | 17% |
| Nausea | 34% to 53% | Not stated here |
| Fatigue | 16% to 42% | Not stated here |
| Anaemia | 72% to 80% | Not stated here |
| Low lymphocytes | Up to 94% | 44% |
| Raised bilirubin | 48% | 18% grade 3, 5% grade 4 |
| Hair loss | 41% | Not stated here |
Serious side effects
| Side effect | Why it matters |
| Severe diarrhoea | Can be fatal, needs the drug withheld |
| Severe dehydration | Can cause acute kidney injury |
| Neutropenia | Low white cells, serious infection risk |
| Thrombocytopenia | Low platelets, bleeding risk |
| Bleeding with blood thinners | The boxed warning, can be fatal |
| Early-onset severe toxicity | May indicate DPD deficiency |
| Mucositis | Severe mouth and gut lining damage |
| Neurotoxicity | Reported in DPD deficiency |
| Cardiac effects | Chest pain and rhythm changes reported |
| Severe skin reactions | Blistering or peeling rash |
| Raised bilirubin and liver injury | Needs dose interruption |
Drug interactions – avoid with
| Drug or group | What happens and what to do |
| Warfarin and vitamin K antagonists | Bleeding risk, monitor INR often |
| Allopurinol | Avoid, it may reduce the drug effect |
| Leucovorin and folate products | May raise toxicity, monitor closely |
| Folic acid supplements | Do not take unless prescribed |
| Phenytoin | Levels rise, monitor and adjust the dose |
| Other CYP2C9 substrates | Monitor closely |
| Antidiabetic drugs | Effects may change, monitor sugar |
| Platinum salts such as cisplatin | Watch for kidney toxicity |
| Irinotecan | Watch for kidney toxicity |
| Methotrexate | Watch for kidney toxicity |
| Intravenous bisphosphonates | Watch for kidney toxicity |
| Other fluoropyrimidines | Never combine, overlapping toxicity |
| Live vaccines | Discuss timing with the oncology team |

Reviews
There are no reviews yet.